Ironwood Pharmaceuticals (IRWD) Total Non-Current Liabilities (2016 - 2025)
Ironwood Pharmaceuticals (IRWD) has disclosed Total Non-Current Liabilities for 14 consecutive years, with $637.1 million as the latest value for Q4 2025.
- Quarterly Total Non-Current Liabilities changed 0.31% to $637.1 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $637.1 million through Dec 2025, changed 0.31% year-over-year, with the annual reading at $637.1 million for FY2025, 0.31% changed from the prior year.
- Total Non-Current Liabilities hit $637.1 million in Q4 2025 for Ironwood Pharmaceuticals, roughly flat from $638.0 million in the prior quarter.
- In the past five years, Total Non-Current Liabilities ranged from a high of $919.0 million in Q2 2023 to a low of $436.3 million in Q2 2022.
- Historically, Total Non-Current Liabilities has averaged $587.9 million across 5 years, with a median of $594.6 million in 2022.
- Biggest five-year swings in Total Non-Current Liabilities: skyrocketed 110.62% in 2023 and later fell 25.72% in 2024.
- Year by year, Total Non-Current Liabilities stood at $517.5 million in 2021, then decreased by 15.29% to $438.4 million in 2022, then increased by 1.67% to $445.7 million in 2023, then soared by 42.51% to $635.1 million in 2024, then increased by 0.31% to $637.1 million in 2025.
- Business Quant data shows Total Non-Current Liabilities for IRWD at $637.1 million in Q4 2025, $638.0 million in Q3 2025, and $628.6 million in Q2 2025.